65,437 trials
Central Line Associated Bloodstream Infections (CLABSI) · Bone Marrow Transplant
Primary: Rate of Central Line Associated Bloodstream Infections (CLABSI) — 3.69; 4.37 CLABSI/1000 catheter-days
Major Depressive Disorder
Primary: Change From Baseline to End of Treatment (Week 6) in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score — -4.8; -4.6 units on a scale — p=0.782
Pancreatic Ductal Adenocarcinoma
Primary: Stage 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)…
Prader-Willi Syndrome
Primary: Suck and Swallow Competency in Infants/Children With PWS Who Are in Nutritional Phase 1a — 8; 4; 1; 1 Participants — p=0.930
Obstructive Sleep Apnea
Primary: Subjective Questionnaire of Mask Experience — 8.08; 8.12 units on a scale
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in Trough (Forced Expiratory Volume (FEV1) (Pre-dose FEV1) — 0.17; 0.18 Liter
Pseudomonas Aeruginosa Infection
Primary: Pulmonary Function Test: Forced Expiratory Volume in 1 Second (FEV1) — 0.47; 1.67 Percent (%) change
Renal Cell Carcinoma
Primary: PFS (Progression-Free Survival) — 27.71 Weeks
Lung Cancer, Non-Small Cell · Non-Small-Cell Lung Cancer
Primary: Median Time of Overall Survival — 30.7; 28.6 Weeks — p=0.9460
Diabetes Mellitus, Type 1
Primary: Concentration of Epinephrine — 157.2; 196.5; 607.5; 525.2 picomole per liter (pmol/L)
Prostatic Hyperplasia
Primary: Number of Men With Confirmed Diagnosis of BPH — 386; 437 Participants
Hepatitis C Virus
Primary: Percentage of Participants Who Achieved Sustained Virologic Response (SVR12) at Follow-Up Week 12 — 91.7; 89.7 Percentage of participants
Rheumatoid Arthritis · Psoriatic Arthritis · Axial Spondyloarthritis
Primary: Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 12 — 194 Participants
Parkinson's Disease Psychosis
Primary: Safety: Number (%) of Patients With Drug-related Treatment-emergent Adverse Events (AEs) — 180 Participants
Rhinitis, Allergic, Seasonal
Primary: Number of Participants Who Used the Test Product at Correct Age (18 Years or Older) — 45 Participants